Optical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, as Director
March 14 2014 - 07:55AM
Business Wire
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an
FDA approved optical diagnostic device that assists dermatologists
in melanoma diagnosis, today announced the appointment of veteran
medical device investment banker Samuel E. Navarro to the Board of
Directors. Mr. Navarro’s appointment brings MELA’s Board to eight
members.
Mr. Navarro brings a wealth of knowledge and industry expertise
in finance, investment banking, mergers and acquisitions, equity
research and investment management experience in the medical device
industry. Mr. Navarro is currently Managing Partner at Gravitas
Healthcare, LLC. Before Gravitas, Mr. Navarro was Managing Director
of Cowen & Co. in New York City and head of their Medical
Technology Investment Banking initiatives, leading a team of senior
people, and was responsible for building the franchise across all
product categories, including M&A/Advisory and financing
services and products. Before Cowen & Co., Mr. Navarro spent
over four years at The Galleon Group running the Galleon Healthcare
Fund as a Senior Portfolio Manager. He was responsible for all
healthcare investments across all sectors, including
pharmaceuticals / biopharmaceutical industries, medical technology
and hospital supplies, and all areas of healthcare services. Prior
to Galleon, Mr. Navarro was Global Head of Healthcare Investment
Banking at ING Barings.
Mr. Navarro has also served or serves on the boards of Arstasis,
MicroTherapeutics, Jomed, Photomedex and Pixelux Entertainment. Mr.
Navarro received an MBA in Finance from The Wharton School at the
University of Pennsylvania, a Master of Science in Engineering from
Stanford University and a Bachelor of Science in Engineering from
The University of Texas at Austin.
Mr. Navarro commented, “I am excited to contribute to the MELA
Sciences Board as they execute their U.S. and European
commercialization strategy for MelaFind and develop plans for other
global markets. I also look forward to working with the company to
evaluate and develop other potential applications for their optical
diagnostic technology.”
Rose Crane, CEO of MELA Sciences said, “Sam brings a tremendous
breadth of experience, expertise and relationships across the
medical device and healthcare industry and huge enthusiasm
regarding MELA Sciences and our potential. We look forward to the
vital insight and guidance Sam will provide as we move
forward.”
Please follow us:
Twitter:
@MELASciencesIR or @MelaFind
StockTwits:
@MELASciencesIR
Facebook:
MELA Sciences or MelaFind
BoardVote:
MELA
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
flagship product is MelaFind®, an FDA, PMA and CE Mark approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's cell structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA
is also exploring new potential uses for its core imaging
technology and algorithms.
Safe Harbor
This press release includes "forward-looking statements" within
the meaning of the Securities Litigation Reform Act of 1995. These
statements include but are not limited to our plans, objectives,
expectations and intentions and may contain words such as “seeks,”
“look forward,” and “there seems” that suggest future events or
trends. These statements are based on our current expectations and
are inherently subject to significant uncertainties and changes in
circumstances. Actual results may differ materially from our
expectations due to financial, economic, business, competitive,
market, regulatory and political factors or conditions affecting
the company and the medical device industry in general, as well as
more specific risks and uncertainties set forth in the company’s
SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any
or all of these forward-looking statements may prove to be
incorrect or unreliable. MELA Sciences assumes no duty to update
its forward-looking statements and urges investors to carefully
review its SEC disclosures available at www.sec.gov and
www.melasciences.com.
MediaMELA Sciences, Inc.Diana Garcia Redruello,
212-518-4226dgarcia@melasciences.comorInvestorsCatalyst
GlobalToni Trigiani, David Collins,
212-924-9800mela@catalyst-ir.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2023 to Mar 2024